Rafael Hernani

14PUBLICATIONS
66CO-AUTHORS
Molecular targetsHaematological tumoursPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jan 26, 2026
Microbiome-Based Modeling of CAR-T Therapy Response in Lymphoma: Insights From Shotgun Metagenomics Sequencing.

Rafael Hernani, Eliseo Albert, Carlos Hernani-Morales

|Oct 07, 2025
Patterns of immune recovery after axicabtagene ciloleucel for aggressive B-cell lymphoma.

André Airosa Pardal, Ana Benzaquén, Pablo Granados

|Mar 20, 2025
Clinical Impact of CD19 Expression Assessed by Quantitative PCR in Lymphoma Patients Undergoing CAR-T Therapy.

Rafael Hernani, Laura Ventura, Begoña Heras

|Oct 24, 2023
Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy.

Gloria Iacoboni, Víctor Navarro, Ana África Martín-López

|Mar 15, 2023
Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era.

Alberto Mussetti, Leyre Bento, Mariana Bastos-Oreiro

|Jul 18, 2022
Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis.

Rafael Hernani, José Luis Piñana, Ariadna Pérez

Pageof 3

Frequent Collaborators

6 joint publications

Juan Montoro Gómez

5 joint publications

Carlos Solano

4 joint publications

David Navarro

4 joint publications

Christelle Ferrà